Last reviewed · How we verify
Human BCMA Targeted T Cells Injection
BCMA-targeted T cells
BCMA-targeted T cells Used for Multiple myeloma.
At a glance
| Generic name | Human BCMA Targeted T Cells Injection |
|---|---|
| Also known as | BCMA CAR-T |
| Sponsor | Hrain Biotechnology Co., Ltd. |
| Drug class | CAR-T cell therapy |
| Target | BCMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BCMA-targeted T cells are a type of immunotherapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells.
Approved indications
- Multiple myeloma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Key clinical trials
- A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). (PHASE1)
- IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (EARLY_PHASE1)
- Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis (PHASE2)
- An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (PHASE1)
- A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (PHASE1)
- Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM (PHASE2)
- A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) (PHASE1)
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: